Meenakshi Mission Hospital Performs South Tamil Nadu’s First High Risk Angioplasty Assisted by Impella Heart Pump

Madurai, December 24 2020: Meenakshi Mission Hospital and Research Centre - Madurai becomes the first hospital in South Tamil Nadu to perform angioplasty heart surgery assisted by a mechanical heart pump called Impella which takes over the heart’s function during the procedure. 

(L to R) Dr. N. Ganesan, Sr. Consultant- Interventional Cardiology,Meenakshi Misson Hospital and Research Center, Madurai, Patient Yesodha (77)& Dr R. Sivakumar, Senior Consultant - Interventional Cardiology, Meenakshi Misson Hospital and Research Center, Madurai

Known as Protected Percutaneous Coronary Intervention (Protected PCI), the procedure was performed on December 18th on a 77-year-old lady by a team headed by Dr R. Sivakumar, Senior Consultant - Interventional Cardiology, Meenakshi Misson Hospital and Research Center, Madurai. The patient is fully recovered and is fit to resume her normal life. Impella was removed after the surgery. Both the insertion and removal of the heart pump, the smallest in the world that measures 14 French (Fr) or 4.62 millimeters in diameter upon insertion and removal, was done through the groin artery.

When a angioplasty is performed on a patient whose heart is too weak - owing to factors like over calcification and severe blockage of arteries, even a minimally-invasive heart surgery like angioplasty can overwhelm the heart and make it stop, causing death. But Impella can bring down the mortality rate during the angioplasty from over 25% to less than 5% by helping the heart rest and recover during the surgery by taking over its function temporarily. The pump can do the heart’s function up to 7 days post-surgery, when required. 

In his comments about the new Impella assisted surgery, Dr Guru Shankar, Chairman, Meenakshi Mission Hospital and Research Centre, Madurai said that Impella is considered a boon for patients who have a weak and failing heart, and for whom performing even a minimally-invasive heart surgery like angioplasty can overwhelm the heart and make it stop. With Impella, this risk is reduced significantly. Impella is in use in the US and Europe for a few years but it is approved in India in 2018. Though two surgeries, assisted by Impella, were performed in Tamil Nadu - one in Chennai, and another in Vellore, this is the first time a hospital In South Tamil Nadu performed it. 

In his comments, Dr. R. Sivakumar, said that the patient with known heart disease since 2012 developed a critical block with a thick chunk of calcium in her main coronary artery. With this condition, doing angioplasty without mechanical circulatory support will be a disaster. Hence we opted for Protected PCI with Impella. We inserted this heart pump before angioplasty. We cleared the calcific block using intracoronary lithotripsy. The entire procedure was done under intracoronary imaging. 

Dr.R.Sivakumar said that the traditional method is to use an Intra Aortic Balloon Pump to inflate and deflate when placed in Aorta to help the heart pump more blood out to the body while using less energy. It is a non-motorized pulsatile pump. It will be of no use if the heart stops functioning during high risk angioplasty. 

However, Impella is a Continuous Axial Flow Pump. It is a heart pump that can temporarily assist the pumping function of the heart. Hence Impella makes an invasive or minimally invasive coronary intervention safe, as even when the heart stops functioning, this mechanical device can ensure that blood is pumped out of the heart and provide the critical hemodynamic stability - the state when stable blood flow in the heart and vessels is maintained to support normal functions of all organs. 

Dr.N.Ganesan, Sr.Consultant- Interventional Cardiology, Meenakshi Mission hospital said that acute heart attack complicated by cardiogenic shock (AMI-CS) is associated with in-hospital mortality between 55% -85%. Prior to the advent of percutaneous heart pump, prompt angioplasty with the addition of vasopressors and inotropes (to improve BP) were the standard of care in the management of this critical population which is associated with high mortality of 55%. If the cause of refractory shock is LV failure, escalation of LV support should be considered. Rapid left ventricular hemodynamic support using the Impella pumps improve outcomes and result in survival to device explant of 89% and survival to discharge of 84%. The biggest advantage is safety – we believe this device allows patients to get safely through high-risk procedures, and hospital stay will be shorter and less complicated.

Protected PCI with Impella is becoming a widely accepted stent procedure in patients with a combination of severe coronary artery disease, and other conditions such as diabetes, heart failure, advanced age, complex lesions, rest angina with unstable haemodynamics prior to the high risk angioplasty.

****

 


Popular posts from this blog

மக்கள் படை கட்சியின் 2026 சட்டமன்ற வேட்பாளர் பட்டியல் வெளியீடு – பொதுச் செயலாளர் ராம்பிரகாஷ் அறிவிப்பு

THANC Hospital Opens 'Chennai Breast Centre' | Focuses on Women's Health & Breast Cancer Awareness

𝘊𝘩𝘦𝘯𝘯𝘢𝘪 𝘏𝘰𝘴𝘵𝘴 64𝘵𝘩 𝘈𝘎𝘔 & 𝘕𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘊𝘰𝘯𝘧𝘦𝘳𝘦𝘯𝘤𝘦 𝘰𝘧 𝘍𝘦𝘥𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘗𝘢𝘱𝘦𝘳 𝘛𝘳𝘢𝘥𝘦𝘳𝘴 𝘈𝘴𝘴𝘰𝘤𝘪𝘢𝘵𝘪𝘰𝘯𝘴 𝘰𝘧 𝘐𝘯𝘥𝘪𝘢 (𝘍𝘗𝘛𝘈)

𝘒𝘢𝘶𝘷𝘦𝘳𝘺 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘝𝘢𝘥𝘢𝘱𝘢𝘭𝘢𝘯𝘪 𝘐𝘯𝘵𝘳𝘰𝘥𝘶𝘤𝘦𝘴 𝘍𝘳𝘦𝘦 𝘔𝘰𝘣𝘪𝘭𝘦 𝘓𝘶𝘯𝘨 𝘊𝘭𝘪𝘯𝘪𝘤 – “𝘒𝘢𝘶𝘷𝘦𝘳𝘺 𝘉𝘳𝘦𝘢𝘵𝘩 𝘊𝘩𝘦𝘤𝘬” 𝘧𝘰𝘳 𝘊𝘩𝘦𝘯𝘯𝘢𝘪 & 𝘚𝘶𝘳𝘳𝘰𝘶𝘯𝘥𝘪𝘯𝘨 𝘈𝘳𝘦𝘢𝘴

𝘗𝘢𝘶𝘭𝘴𝘰𝘯𝘴 𝘉𝘦𝘢𝘶𝘵𝘺 & 𝘍𝘢𝘴𝘩𝘪𝘰𝘯 𝘗𝘷𝘵. 𝘓𝘵𝘥. 𝘜𝘯𝘷𝘦𝘪𝘭𝘴 𝘗𝘪𝘯𝘬 𝘗𝘰𝘵𝘢𝘵𝘰 – 𝘈 𝘊𝘩𝘪𝘤 𝘝𝘦𝘨𝘦𝘵𝘢𝘳𝘪𝘢𝘯 𝘋𝘪𝘯𝘪𝘯𝘨 𝘋𝘦𝘴𝘵𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘪𝘯 𝘗𝘰𝘦𝘴 𝘎𝘢𝘳𝘥𝘦𝘯